Iproteos, IBEC and VHIR to develop a therapy against solid tumors

by Gemma Escarré,

The biotechnology company Iproteos and the Institute of Bioengineering of Catalonia (IBEC), CataloniaBio & HealthTech members, and the Vall d'Hebron Research Institute (VHIR) are set to develop an innovative treatment to slow down, stop and even reverse the growth of solid tumors, which represent more than 90% of cancer cases. 

The project, which received €935,000 from the Spanish Ministry of Science, Innovation and Universities, through of the call 2017 Retos, will focus in its first phase on two of the most common solid tumors in children and adolescents, rhabdomyosarcoma and neuroblastoma, as well as in lung and colon cancer, which have the highest mortality rate in adults.

The ultimate goal is to validate a family of peptidomimetic compounds (new generation drugs able to cross the cell membrane) with a totally new mechanism for cancer treatment, in order to carry out preclinical regulatory trials.

More information

Photo: From left to right, Dr Pere Roca (IBEC), Dr Teresa Tarragó (Iproteos) and Dr Josep Roma (VHIR) - © Barcelona Science Park


To comment, please login or create an account